Artivion Reports First Quarter 2025 Financial Results
- Revenue increased 2% YoY to $99.0 million (4% on constant currency basis)
- Strong product growth: stent grafts +14%, On-X +10%, BioGlue +7%
- Raised 2025 revenue guidance to $423-435 million
- Adjusted EBITDA expected to grow 18-28% in 2025
- NEXUS trial showed 63% reduction in major adverse events
- Submitted clinical module of PMA to FDA for AMDS Hybrid Prosthesis
- Net loss of $(0.5) million in Q1 2025 vs. net income of $7.5 million in Q1 2024
- 23% decrease in preservation services revenue due to cybersecurity incident
- Adjusted EBITDA growth was modest at 1% YoY
Insights
Artivion showed mixed Q1 results with product growth offset by cybersecurity-related declines; raised revenue guidance indicates confidence despite current challenges.
Artivion's Q1 2025 financial results present a mixed picture. Total revenue reached
This product growth was significantly offset by a
On a non-GAAP basis, the company maintained stability with net income of
Management's decision to raise the midpoint of their 2025 revenue guidance to
Strong clinical trial results for NEXUS stent graft system and PMA submission for AMDS Hybrid Prosthesis advance Artivion's aortic disease pipeline.
The 30-day data from Endospan's NEXUS TRIOMPHE IDE trial represents a significant clinical milestone for Artivion's aortic disease portfolio. The trial results presented at the AATS Annual Meeting demonstrated a
The company also advanced its regulatory strategy by submitting the clinical module of the pre-market approval application (PMA) to the FDA for its AMDS Hybrid Prosthesis. These regulatory milestones reinforce Artivion's growing pipeline in the aortic disease space and provide visibility into future growth catalysts.
From an operational perspective, Artivion demonstrated resilience in responding to a cybersecurity incident that significantly impacted its tissue processing operations. Management indicated they outpaced initial expectations in returning to standard processing times, contributing to stronger-than-anticipated Q1 performance despite the
The combination of strong product growth in stent grafts (
First Quarter Highlights:
- Achieved revenue of
$99.0 million $97.4 million 2% on a GAAP basis and4% on a non-GAAP constant currency basis - Net loss was
$(0.5) million $(0.01) $2.5 million $0.06 - Adjusted EBITDA increased
1% to$17.5 million $17.3 million - 30-day data from Endospan's NEXUS TRIOMPHE IDE trial presented at the AATS Annual Meeting demonstrated a
63% reduction in the major adverse event (MAE) rate compared with reference performance goal - Submitted the clinical module of the pre-market approval application (PMA) to the FDA for the AMDS Hybrid Prosthesis
"I am pleased with our first quarter results as we returned to normal operations following our previously disclosed cybersecurity incident while making substantial progress on our strategic growth initiatives. As anticipated, our performance was driven by year-over-year growth in stent grafts of
Mr. Mackin added, "Given our strong first quarter performance, we are raising the midpoint of our full year revenue expectations for 2025 and remain confident in our ability to grow adjusted EBITDA at twice the rate of constant currency revenue growth."
Mr. Mackin concluded, "We were also pleased to see Endospan present positive new clinical data for its NEXUS aortic stent graft system at the AATS Annual Meeting in May. Trial data out to 30 days met its primary endpoints and demonstrated statistically significant improvement in clinical outcomes compared with the goals set in the investigational protocol. With these outcomes, we believe NEXUS remains on track for FDA approval in the second half of 2026 and we look forward to Endospan sharing 1-year follow up data next year."
First Quarter 2025 Financial Results
Total revenues for the first quarter of 2025 were
Net loss for the first quarter of 2025 was
2025 Financial Outlook
Artivion is raising the midpoint of its revenue guidance and now expects full year 2025 revenue to be in the range of
Additionally, Artivion continues to expect adjusted EBITDA growth of between
The Company's financial performance for 2025 and future periods is subject to the risks identified below.
Non-GAAP Financial Measures
This press release contains non-GAAP financial measures, including non-GAAP revenue, non-GAAP net income and diluted EPS, EBITDA, adjusted EBITDA, non-GAAP general, administrative, and marketing expenses, and free cash flows. Investors should consider this non-GAAP information in addition to, and not as a substitute for, financial measures prepared in accordance with US GAAP. In addition, this non-GAAP financial information may not be the same as similar measures presented by other companies. The Company's non-GAAP revenues are adjusted for the impact of changes in currency exchange. The Company's non-GAAP net income, EBITDA, adjusted EBITDA, general, administrative, and marketing, and free cash flows results primarily exclude (as applicable) depreciation and amortization expense, interest income and expense, non-cash compensation expense, loss or gain on foreign currency revaluation, income tax expense or benefit, business development, integration, and severance income or expense, loss on extinguishment of debt, non-cash interest expense, capital expenditures, and other non-recurring items.
The Company generally uses non-GAAP financial measures to facilitate management's review of the operational performance of the Company and as a basis for strategic planning. Company management believes that these non-GAAP presentations provide useful information to investors regarding unusual non-operating transactions, the operating expense structure of the Company's existing and acquired operations, without regard to its on-going efforts to acquire additional complementary products and businesses, and the transaction and integration expenses incurred in connection with recently acquired and divested product lines, and the operating expense structure excluding fluctuations resulting from foreign currency revaluation and non-cash compensation expense. The Company believes it is useful to exclude certain expenses and revenues because such amounts in any specific period may not directly correlate to the underlying performance of its business operations or can vary significantly between periods as a result of factors such as impact of recent acquisitions, non-cash expense related to amortization of previously acquired tangible and intangible assets, and any related adjustments to their carrying values. The Company has adjusted for the impact of changes in currency exchange from certain revenues to evaluate comparable product growth rates on a constant currency basis. The Company does, however, expect to incur similar types of expenses and currency exchange impacts in the future, and this non-GAAP financial information should not be viewed as a statement or indication that these types of expenses will not recur. Company management encourages investors to review the Company's consolidated financial statements and publicly filed reports in their entirety, including the reconciliation of GAAP to non-GAAP financial measures.
The Company's adjusted EBITDA expectations for fiscal 2025 exclude potential charges or gains that may be recorded during the fiscal year, relating to, among other things, non-cash compensation, business development, integration, and severance income or expense, loss on extinguishment of debt, and foreign currency revaluations. The Company does not attempt to provide reconciliations of forward-looking adjusted EBITDA to the comparable GAAP measure because the impact and timing of these potential charges or gains are inherently uncertain and difficult to predict and are unavailable without unreasonable efforts. In addition, the Company believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors. Such items could have a material impact on GAAP measures of the Company's financial performance.
Webcast and Conference Call Information
The Company will hold a teleconference call and live webcast on May 5, 2025, at 4:30 p.m. ET to discuss the results, followed by a question-and-answer session. To participate in the conference call dial 201-689-8261 a few minutes prior to 4:30 p.m. ET. The teleconference replay will be available approximately one hour following the completion of the event and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13752340.
The live webcast and replay can be accessed by going to the Investors section of the Artivion website at www.Artivion.com and selecting the heading Webcasts & Presentations.
About Artivion, Inc.
Headquartered in suburban
Forward-Looking Statements
Statements made in this press release that look forward in time or that express management's beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include, but are not limited to, our beliefs and expectations about our revenue, year-over-year growth and growth drivers, earnings, currency impacts, and other financial measures and related information; our anticipated capital needs and capital structure; our beliefs about our competitive advantages and market opportunities; the expected impact on our business of the dynamic trade policy and tariff environment; our expected product mix and business strategy; anticipated quarterly fluctuations in our business; our beliefs and expectations about the impact of the November 2024 cybersecurity incident, including our expected timeline for returning to normal levels of inventory and backlog; the timeline for regulatory approval for AMDS and other products, including our expectation that NEXUS is on track to obtain FDA approval in the second half of 2026; the benefits of receiving the Humanitarian Device Exemption and Breakthrough Designation for AMDS; our expected geographies and timeframes for commercializing our products; that our revenues for the full year 2025 will be in the range of
Artivion, Inc. and Subsidiaries Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income In Thousands, Except Per Share Data (Unaudited)
| |||
Three Months Ended | |||
2025 | 2024 | ||
Revenues: | |||
Products | $ 78,798 | $ 71,114 | |
Preservation services | 20,180 | 26,317 | |
Total revenues | 98,978 | 97,431 | |
Cost of products and preservation services: | |||
Products | 25,263 | 23,750 | |
Preservation services | 10,138 | 10,735 | |
Total cost of products and preservation services | 35,401 | 34,485 | |
Gross margin | 63,577 | 62,946 | |
Operating expenses: | |||
General, administrative, and marketing | 54,704 | 30,689 | |
Research and development | 6,728 | 6,946 | |
Total operating expenses | 61,432 | 37,635 | |
Operating income | 2,145 | 25,311 | |
Interest expense | 7,663 | 7,826 | |
Interest income | (144) | (374) | |
Loss on extinguishment of debt | — | 3,669 | |
Other (income) expense, net | (3,079) | 1,409 | |
(Loss) income before income taxes | (2,295) | 12,781 | |
Income tax (benefit) expense | (1,790) | 5,248 | |
Net (loss) income | $ (505) | $ 7,533 | |
(Loss) income per share: | |||
Basic | $ (0.01) | $ 0.18 | |
Diluted | $ (0.01) | $ 0.18 | |
Weighted-average common shares outstanding: | |||
Basic | 42,232 | 41,290 | |
Diluted | 42,232 | 47,886 | |
Net (loss) income | $ (505) | $ 7,533 | |
Other comprehensive income: | |||
Foreign currency translation adjustments, net of tax | 6,331 | (1,528) | |
Comprehensive income | $ 5,826 | $ 6,005 | |
Artivion, Inc. and Subsidiaries Condensed Consolidated Balance Sheets In Thousands
| |||
March 31, | December 31, | ||
(Unaudited) | |||
ASSETS | |||
Current assets: | |||
Cash and cash equivalents | $ 37,693 | $ 53,463 | |
Trade receivables, net | 87,802 | 79,462 | |
Other receivables | 7,956 | 6,431 | |
Inventories | 81,927 | 79,766 | |
Deferred preservation costs | 52,375 | 51,701 | |
Prepaid expenses and other | 19,544 | 19,257 | |
Total current assets | 287,297 | 290,080 | |
Goodwill | 245,069 | 240,958 | |
Acquired technology, net | 127,530 | 128,051 | |
Operating lease right-of-use assets, net | 39,229 | 39,726 | |
Property and equipment, net | 37,810 | 36,403 | |
Other intangibles, net | 28,517 | 28,332 | |
Deferred tax assets, net | 684 | 1,068 | |
Other long-term assets | 25,027 | 24,483 | |
Total assets | $ 791,163 | $ 789,101 | |
LIABILITIES AND STOCKHOLDERS' EQUITY | |||
Current liabilities: | |||
Accounts payable | $ 11,695 | $ 17,971 | |
Accrued compensation | 12,294 | 18,342 | |
Accrued expenses | 11,520 | 11,834 | |
Accrued interest | 6,757 | 8,170 | |
Taxes payable | 1,605 | 2,934 | |
Accrued procurement fees | 1,982 | 1,704 | |
Current maturities of operating leases | 4,575 | 4,489 | |
Current portion of finance lease obligations | 669 | 601 | |
Current portion of long-term debt, net | 135 | 195 | |
Other current liabilities | 708 | 583 | |
Total current liabilities | 51,940 | 66,823 | |
Long-term debt, net | 314,611 | 314,152 | |
Contingent consideration | 50,050 | 52,880 | |
Non-current maturities of operating leases | 39,353 | 39,988 | |
Deferred tax liabilities, net | 21,532 | 20,183 | |
Deferred compensation liability | 8,070 | 7,977 | |
Non-current finance lease obligations | 3,016 | 2,833 | |
Other long-term liabilities | 8,339 | 8,065 | |
Total liabilities | $ 496,911 | $ 512,901 | |
Commitments and contingencies | |||
Stockholders' equity: | |||
Preferred stock | — | — | |
Common stock | 442 | 434 | |
Additional paid-in capital | 388,825 | 376,607 | |
Retained deficit | (61,771) | (61,266) | |
Accumulated other comprehensive loss | (18,596) | (24,927) | |
Treasury stock, at cost, 1,487 shares as of March 31, 2025 and December 31, 2024 | (14,648) | (14,648) | |
Total stockholders' equity | 294,252 | 276,200 | |
Total liabilities and stockholders' equity | $ 791,163 | $ 789,101 | |
Artivion, Inc. and Subsidiaries Condensed Consolidated Statement of Cash Flows In Thousands (Unaudited)
| |||
Three Months Ended | |||
2025 | 2024 | ||
Net cash flows from operating activities: | |||
Net (loss) income | $ (505) | $ 7,533 | |
Adjustments to reconcile net (loss) income to net cash from operating activities: | |||
Depreciation and amortization | 5,446 | 5,909 | |
Non-cash compensation | 8,045 | 3,478 | |
Non-cash lease expense | 1,226 | 1,920 | |
Write-down of inventories and deferred preservation costs | 1,312 | 723 | |
Deferred income taxes | — | 4,299 | |
Change in fair value of contingent consideration | (2,830) | (17,470) | |
Loss on extinguishment of debt | — | 3,669 | |
Other | (2,891) | 644 | |
Changes in operating assets and liabilities: | |||
Receivables | (7,922) | (3,334) | |
Inventories and deferred preservation costs | (2,453) | (1,380) | |
Prepaid expenses and other assets | (327) | (2,268) | |
Accounts payable, accrued expenses, and other liabilities | (16,054) | (9,216) | |
Net cash flows used in operating activities | (16,953) | (5,493) | |
Net cash flows from investing activities: | |||
Capital expenditures | (3,638) | (3,611) | |
Net cash flows used in investing activities | (3,638) | (3,611) | |
Net cash flows from financing activities: | |||
Proceeds from issuance of long-term debt | — | 190,000 | |
Proceeds from revolving credit facility | — | 30,000 | |
Repayment of debt | (66) | (211,627) | |
Proceeds from exercise of stock options and issuance of common stock | 4,181 | 3,528 | |
Payment of debt issuance costs | — | (9,998) | |
Principal payments on short-term notes payable | — | (1,027) | |
Other | (178) | (139) | |
Net cash flows provided by financing activities | 3,937 | 737 | |
Effect of exchange rate changes on cash and cash equivalents | 884 | 545 | |
Decrease in cash and cash equivalents | (15,770) | (7,822) | |
Cash and cash equivalents beginning of period | 53,463 | 58,940 | |
Cash and cash equivalents end of period | $ 37,693 | $ 51,118 | |
Artivion, Inc. and Subsidiaries Financial Highlights In Thousands (Unaudited)
| |||
Three Months Ended | |||
2025 | 2024 | ||
Products: | |||
Aortic stent grafts | $ 36,602 | $ 32,103 | |
On-X | 21,574 | 19,681 | |
Surgical sealants | 18,106 | 16,981 | |
Other | 2,516 | 2,349 | |
Total products | 78,798 | 71,114 | |
Preservation services | 20,180 | 26,317 | |
Total revenues | $ 98,978 | $ 97,431 | |
47,793 | 50,928 | ||
37,045 | 33,588 | ||
8,214 | 7,609 | ||
5,926 | 5,306 | ||
Total revenues | $ 98,978 | $ 97,431 | |
Artivion, Inc. and Subsidiaries Reconciliation of GAAP to Non-GAAP Revenues $ In Thousands (Unaudited)
| |||||||||
Revenues for the Three Months Ended March 31, | Percent Change From Prior Year | ||||||||
2025 | 2024 | ||||||||
US GAAP | US GAAP | Exchange | Constant | Constant | |||||
Products: | |||||||||
Aortic stent grafts | $ 36,602 | $ 32,103 | $ (1,308) | $ 30,795 | 19 % | ||||
On-X | 21,574 | 19,681 | (272) | 19,409 | 11 % | ||||
Surgical sealants | 18,106 | 16,981 | (317) | 16,664 | 9 % | ||||
Other | 2,516 | 2,349 | (4) | 2,345 | 7 % | ||||
Total products | 78,798 | 71,114 | (1,901) | 69,213 | 14 % | ||||
Preservation services | 20,180 | 26,317 | (67) | 26,250 | -23 % | ||||
Total | $ 98,978 | $ 97,431 | $ (1,968) | $ 95,463 | 4 % | ||||
47,793 | 50,928 | (152) | 50,776 | -6 % | |||||
37,045 | 33,588 | (1,210) | 32,378 | 14 % | |||||
8,214 | 7,609 | — | 7,609 | 8 % | |||||
5,926 | 5,306 | (606) | 4,700 | 26 % | |||||
Total | $ 98,978 | $ 97,431 | $ (1,968) | $ 95,463 | 4 % | ||||
Artivion, Inc. and Subsidiaries Reconciliation of GAAP to Non-GAAP General, Administrative, and Marketing Expense, EBITDA, Adjusted EBITDA, and Free Cash Flows In Thousands (Unaudited)
| |||
Three Months Ended | |||
2025 | 2024 | ||
Reconciliation of G&A expenses, GAAP to adjusted G&A, non-GAAP: | |||
General, administrative, and marketing expense, GAAP | $ 54,704 | $ 30,689 | |
Business development, integration, and severance income | (2,784) | (17,387) | |
Cybersecurity incident | 4,450 | — | |
Adjusted G&A, non-GAAP | $ 53,038 | $ 48,076 | |
Three Months Ended | |||
2025 | 2024 | ||
Reconciliation of net (loss) income, GAAP and EBITDA, non-GAAP to adjusted EBITDA, non-GAAP: | |||
Net (loss) income, GAAP | $ (505) | $ 7,533 | |
Adjustments: | |||
Interest expense | 7,663 | 7,826 | |
Interest income | (144) | (374) | |
Income tax (benefit) expense | (1,790) | 5,248 | |
Depreciation and amortization expense | 5,446 | 5,909 | |
EBITDA, non-GAAP | 10,670 | 26,142 | |
Non-cash compensation | 8,045 | 3,478 | |
Business development, integration, and severance income | (3,057) | (17,387) | |
Cybersecurity incident | 4,746 | — | |
Loss on extinguishment of debt | — | 3,669 | |
(Gain) loss on foreign currency revaluation | (2,856) | 1,410 | |
Adjusted EBITDA, non-GAAP | $ 17,548 | $ 17,312 | |
Three Months Ended | |||
2025 | 2024 | ||
Reconciliation of cash flows from operating activities, GAAP to free cash flows, non-GAAP: | |||
Net cash flows provided by operating activities | (16,953) | (5,493) | |
Capital expenditures | (3,638) | (3,611) | |
Free cash flows, non-GAAP | $ (20,591) | $ (9,104) | |
Artivion Inc. and Subsidiaries Reconciliation of GAAP to Non-GAAP Net Income and Diluted Income Per Common Share In Thousands, Except Per Share Data (Unaudited)
| |||
Three Months Ended | |||
2025 | 2024 | ||
GAAP: | |||
(Loss) income before income taxes | $ (2,295) | $ 12,781 | |
Income tax (benefit) expense | $ (1,790) | $ 5,248 | |
Net (loss) income | $ (505) | $ 7,533 | |
Diluted (loss) income per common share | $ (0.01) | $ 0.18 | |
Diluted weighted-average common shares outstanding | 42,232 | 47,886 | |
Reconciliation of (loss) income before income taxes, GAAP to adjusted income, non-GAAP: | |||
(Loss) income before income taxes, GAAP: | $ (2,295) | $ 12,781 | |
Adjustments: | |||
Amortization expense | 3,388 | 3,867 | |
Business development, integration, and severance income | (3,057) | (17,387) | |
Non-cash interest expense | 543 | 580 | |
Cybersecurity incident | 4,746 | — | |
Loss on extinguishment of debt | — | 3,669 | |
Adjusted income before income taxes, non-GAAP | 3,325 | 3,510 | |
Income tax expense calculated at a tax rate of | 831 | 878 | |
Adjusted net income, non-GAAP | $ 2,494 | $ 2,632 | |
Reconciliation of diluted (loss) income per common share, GAAP to adjusted diluted income per common share, non-GAAP: | |||
Diluted (loss) income per common share, GAAP: | $ (0.01) | $ 0.18 | |
Adjustments: | |||
Amortization expense | 0.08 | 0.09 | |
Business development, integration, and severance income | (0.07) | (0.41) | |
Non-cash interest expense | 0.01 | 0.01 | |
Cybersecurity incident | 0.11 | — | |
Loss on extinguishment of debt | — | 0.09 | |
Tax effect of non-GAAP adjustments | (0.03) | 0.05 | |
Effect of | (0.03) | 0.05 | |
Adjusted diluted income per common share, non-GAAP | $ 0.06 | $ 0.06 | |
Reconciliation of diluted weighted-average common shares outstanding GAAP to diluted weighted-average common shares outstanding, non-GAAP: | |||
Diluted weighted-average common shares outstanding, GAAP: | 42,232 | 47,886 | |
Adjustments: | |||
Effect of dilutive stock options and awards | 1,306 | — | |
Effect of convertible senior notes | — | (5,707) | |
Diluted weighted-average common shares outstanding, non-GAAP | 43,538 | 42,179 | |
Contacts: | |
Artivion | Gilmartin Group LLC |
Lance A. Berry | Brian Johnston / Laine Morgan |
Executive Vice President & | Phone: 332-895-3222 |
Chief Financial Officer | investors@artivion.com |
Phone: 770-419-3355 | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-reports-first-quarter-2025-financial-results-302446214.html
SOURCE Artivion, Inc.
FAQ
What were Artivion's (AORT) Q1 2025 revenue and earnings?
How did Artivion's key product segments perform in Q1 2025?
What is Artivion's revenue guidance for 2025?
What were the results of Endospan's NEXUS TRIOMPHE IDE trial?
How much EBITDA growth does Artivion expect in 2025?
